Ascertainment of vaccination status by self-report versus source documentation: Impact on measuring COVID-19 vaccine effectiveness
dc.contributor.author | Stephenson, Meagan | |
dc.contributor.author | Olson, Samantha M. | |
dc.contributor.author | Self, Wesley H. | |
dc.contributor.author | Ginde, Adit A. | |
dc.contributor.author | Mohr, Nicholas M. | |
dc.contributor.author | Gaglani, Manjusha | |
dc.contributor.author | Shapiro, Nathan I. | |
dc.contributor.author | Gibbs, Kevin W. | |
dc.contributor.author | Hager, David N. | |
dc.contributor.author | Prekker, Matthew E. | |
dc.contributor.author | Gong, Michelle N. | |
dc.contributor.author | Steingrub, Jay S. | |
dc.contributor.author | Peltan, Ithan D. | |
dc.contributor.author | Martin, Emily T. | |
dc.contributor.author | Reddy, Raju | |
dc.contributor.author | Busse, Laurence W. | |
dc.contributor.author | Duggal, Abhijit | |
dc.contributor.author | Wilson, Jennifer G. | |
dc.contributor.author | Qadir, Nida | |
dc.contributor.author | Mallow, Christopher | |
dc.contributor.author | Kwon, Jennie H. | |
dc.contributor.author | Exline, Matthew C. | |
dc.contributor.author | Chappell, James D. | |
dc.contributor.author | Lauring, Adam S. | |
dc.contributor.author | Baughman, Adrienne | |
dc.contributor.author | Lindsell, Christopher J. | |
dc.contributor.author | Hart, Kimberly W. | |
dc.contributor.author | Lewis, Nathaniel M. | |
dc.contributor.author | Patel, Manish M. | |
dc.contributor.author | Tenforde, Mark W. | |
dc.date.accessioned | 2022-11-09T21:20:27Z | |
dc.date.available | 2023-12-09 16:20:26 | en |
dc.date.available | 2022-11-09T21:20:27Z | |
dc.date.issued | 2022-11 | |
dc.identifier.citation | Stephenson, Meagan; Olson, Samantha M.; Self, Wesley H.; Ginde, Adit A.; Mohr, Nicholas M.; Gaglani, Manjusha; Shapiro, Nathan I.; Gibbs, Kevin W.; Hager, David N.; Prekker, Matthew E.; Gong, Michelle N.; Steingrub, Jay S.; Peltan, Ithan D.; Martin, Emily T.; Reddy, Raju; Busse, Laurence W.; Duggal, Abhijit; Wilson, Jennifer G.; Qadir, Nida; Mallow, Christopher; Kwon, Jennie H.; Exline, Matthew C.; Chappell, James D.; Lauring, Adam S.; Baughman, Adrienne; Lindsell, Christopher J.; Hart, Kimberly W.; Lewis, Nathaniel M.; Patel, Manish M.; Tenforde, Mark W. (2022). "Ascertainment of vaccination status by self-report versus source documentation: Impact on measuring COVID-19 vaccine effectiveness." Influenza and Other Respiratory Viruses 16(6): 1101-1111. | |
dc.identifier.issn | 1750-2640 | |
dc.identifier.issn | 1750-2659 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/175131 | |
dc.description.abstract | BackgroundDuring the COVID-19 pandemic, self-reported COVID-19 vaccination might facilitate rapid evaluations of vaccine effectiveness (VE) when source documentation (e.g., immunization information systems [IIS]) is not readily available. We evaluated the concordance of COVID-19 vaccination status ascertained by self-report versus source documentation and its impact on VE estimates.MethodsHospitalized adults (≥18 years) admitted to 18 U.S. medical centers March–June 2021 were enrolled, including COVID-19 cases and SARS-CoV-2 negative controls. Patients were interviewed about COVID-19 vaccination. Abstractors simultaneously searched IIS, medical records, and other sources for vaccination information. To compare vaccination status by self-report and documentation, we estimated percent agreement and unweighted kappa with 95% confidence intervals (CIs). We then calculated VE in preventing COVID-19 hospitalization of full vaccination (2 doses of mRNA product ≥14 days prior to illness onset) independently using data from self-report or source documentation.ResultsOf 2520 patients, 594 (24%) did not have self-reported vaccination information to assign vaccination group; these patients tended to be more severely ill. Among 1924 patients with both self-report and source documentation information, 95.0% (95% CI: 93.9–95.9%) agreement was observed, with a kappa of 0.9127 (95% CI: 0.9109–0.9145). VE was 86% (95% CI: 81–90%) by self-report data only and 85% (95% CI: 81-89%) by source documentation data only.ConclusionsApproximately one-quarter of hospitalized patients could not provide self-report COVID-19 vaccination status. Among patients with self-report information, there was high concordance with source documented status. Self-report may be a reasonable source of COVID-19 vaccination information for timely VE assessment for public health action. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.publisher | Centers for Disease Control and Prevention | |
dc.subject.other | registry | |
dc.subject.other | concordance | |
dc.subject.other | COVID-19 | |
dc.subject.other | self-report | |
dc.subject.other | vaccine effectiveness | |
dc.title | Ascertainment of vaccination status by self-report versus source documentation: Impact on measuring COVID-19 vaccine effectiveness | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Microbiology and Immunology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175131/1/irv13023.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175131/2/irv13023_am.pdf | |
dc.identifier.doi | 10.1111/irv.13023 | |
dc.identifier.source | Influenza and Other Respiratory Viruses | |
dc.identifier.citedreference | Self WH, Tenforde MW, Rhoads JP, et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 Hospitalizations among adults without immunocompromising conditions—United States, March–August 2021. MMWR Morb Mortal Wkly Rep Centers for Disease Control and Prevention. 2021; 70 ( 38 ): 1337 - 1343. | |
dc.identifier.citedreference | Tenforde MW, Olson SM, Self WH, et al. Effectiveness of Pfizer-BioNTech and moderna vaccines against COVID-19 among hospitalized adults aged >/=65 years—United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70 ( 18 ): 674 - 679. | |
dc.identifier.citedreference | Patel MM, Jackson ML, Ferdinands J. Postlicensure evaluation of COVID-19 vaccines. JAMA. 2020; 324 ( 19 ): 1939 - 1940. | |
dc.identifier.citedreference | Dooling K, Gargano JW, Moulia D, et al. Use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years: recommendations of the advisory committee on immunization practices—United States, September 2021. MMWR Morb Mortal Wkly Rep Centers for Disease Control and Prevention. 2021; 70 ( 38 ): 1344 - 1348. | |
dc.identifier.citedreference | COVID-19 Vaccines. US Food and Drug Administration; 2021. | |
dc.identifier.citedreference | COVID Data Tracker. Centers for Disease Control and Prevention; 2021. | |
dc.identifier.citedreference | Tenforde MW, Talbot HK, Trabue CH, et al. Influenza vaccine effectiveness against hospitalization in the United States, 2019-2020. J Infect Dis. 2021; 224 ( 5 ): 813 - 820. | |
dc.identifier.citedreference | Ogokeh CE, Campbell AP, Feldstein LR, et al. Comparison of parental report of influenza vaccination to documented records in children hospitalized with acute respiratory illness, 2015-2016. J Pediatric Infect Dis Soc. 2021; 10 ( 4 ): 389 - 397. | |
dc.identifier.citedreference | An Environmental Scan on Progress, Challenges, and Opportunities: Expanding Immunization Information Systems for Adults in the United States. AIRA; 2020. | |
dc.identifier.citedreference | Early estimates of seasonal influenza vaccine effectiveness—United States, January 2013. MMWR Morb Mortal Wkly Rep. 2013; 62 ( 2 ): 32 - 35. | |
dc.identifier.citedreference | King JP, McLean HQ, Belongia EA. Validation of self-reported influenza vaccination in the current and prior season. Influenza Other Respi Viruses. 2018; 12 ( 6 ): 808 - 813. | |
dc.identifier.citedreference | Britton A, Fleming-Dutra KE, Shang N, et al. Association of COVID-19 vaccination with symptomatic SARS-CoV-2 infection by time since vaccination and delta variant predominance. JAMA. 2022; 327 ( 11 ): 1032 - 1041. | |
dc.identifier.citedreference | Ferdinands JM, Alyanak E, Reed C, Fry AM. Waning of influenza vaccine protection: exploring the trade-offs of changes in vaccination timing among older adults. Clin Infect Dis. 2019; 70 ( 8 ): 1550 - 1559. | |
dc.identifier.citedreference | Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021; 326 ( 20 ): 2043 - 2054. | |
dc.identifier.citedreference | Tenforde MW, Self WH, Naioti EA, et al. Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults—United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021; 70 ( 34 ): 1156 - 1162. | |
dc.identifier.citedreference | Pilishvili T, Fleming-Dutra KE, Farrar JL, et al. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel—33 U.S. Sites, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70 ( 20 ): 753 - 758. | |
dc.identifier.citedreference | White House. Press Briefing by White House COVID-19 Response Team and Public Health Officials. White House; 2021. | |
dc.identifier.citedreference | Rolnick SJ, Parker ED, Nordin JD, et al. Self-report compared to electronic medical record across eight adult vaccines: Do results vary by demographic factors? Vaccine. 2013; 31 ( 37 ): 3928 - 3935. | |
dc.identifier.citedreference | Lu PJ, Srivastav A. Surveillance of vaccination coverage among adult populations—United States 2018. MMWR Surveill Summ. 2021; 70 ( 3 ): 1 - 26. Centers for Disease Control and Prevention. | |
dc.identifier.citedreference | Grohskopf, LA, Alyanak E, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2021–22 Influenza Season. In: Centers for Disease Control and Prevention; August 27, 2021; 2021: 1 - 28. | |
dc.identifier.citedreference | Mass Vaccination Capabilities Summary. AIRA; 2020. | |
dc.identifier.citedreference | Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of messenger RNA coronavirus disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a cohort of healthcare personnel. Clin Infect Dis. 2021; 73 ( 6 ): e1376 - e1379. | |
dc.identifier.citedreference | Pilishvili T, Gierke R, Fleming-Dutra KE, et al. Effectiveness of mRNA Covid-19 vaccine among U.S. health care personnel. N Engl J Med. 2021; | |
dc.identifier.citedreference | Immunization Information Systems. Centers for Disease Control and Prevention. | |
dc.identifier.citedreference | Martin DW, Lowery NE, Brand B, Gold R, Horlick G. Immunization information systems: a decade of progress in law and policy. J Public Health Manag Pract. 2015; 21 ( 3 ): 296 - 303. | |
dc.identifier.citedreference | Mac Donald R, Baken L, Nelson A, Nichol KL. Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients. Am J Prev Med. 1999; 16 ( 3 ): 173 - 177. | |
dc.identifier.citedreference | Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing COVID-19 hospitalizations in the United States. Clin Infect Dis. 2021; | |
dc.identifier.citedreference | Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of BNT162b2 Vaccine against critical Covid-19 in adolescents. N Engl J Med. 2022. | |
dc.identifier.citedreference | Grijalva CG, Feldstein LR, Talbot HK, et al. Influenza vaccine effectiveness for prevention of severe influenza-associated illness among adults in the United States, 2019-2020: A test-negative study. Clin Infect Dis. 2021. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.